RBM42
gene geneOn this page
Also known as MGC10433
Summary
RBM42 (RNA binding motif protein 42, HGNC:28117) is a protein-coding gene on chromosome 19q13.12, encoding RNA-binding protein 42 (Q9BTD8). Binds (via the RRM domain) to the 3’-untranslated region (UTR) of CDKN1A mRNA. It is a selective cancer dependency (DepMap: 73.8% of cell lines).
Enables RNA binding activity. Predicted to be involved in mRNA splicing, via spliceosome. Predicted to act upstream of or within negative regulation of mRNA splicing, via spliceosome. Part of U4/U6 x U5 tri-snRNP complex.
Source: NCBI Gene 79171 — RefSeq curated summary.
At a glance
- Clinical variants (ClinVar): 57 total
- Cancer dependency (DepMap): dependent in 73.8% of screened cell lines
- MANE Select transcript:
NM_024321
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:28117 |
| Approved symbol | RBM42 |
| Name | RNA binding motif protein 42 |
| Location | 19q13.12 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | MGC10433 |
| Ensembl gene | ENSG00000126254 |
| Ensembl biotype | protein_coding |
| OMIM | 613232 |
| Entrez | 79171 |
Gene structure
Transcript identifiers
Ensembl transcripts: 20 — 19 protein_coding, 1 retained_intron
ENST00000262633, ENST00000586618, ENST00000588161, ENST00000589559, ENST00000589871, ENST00000592202, ENST00000592526, ENST00000907957, ENST00000907958, ENST00000907959, ENST00000907960, ENST00000907961, ENST00000907962, ENST00000934967, ENST00000934968, ENST00000943047, ENST00000943048, ENST00000943049, ENST00000943050, ENST00000943051
RefSeq mRNA: 2 — MANE Select: NM_024321
NM_001319113, NM_024321
CCDS: CCDS12468
Canonical transcript exons
ENST00000262633 — 10 exons
| Exon | Start | End |
|---|---|---|
| ENSE00000699956 | 35633687 | 35634019 |
| ENSE00000699957 | 35633077 | 35633252 |
| ENSE00000862798 | 35631331 | 35631405 |
| ENSE00000862799 | 35632936 | 35633001 |
| ENSE00000895634 | 35634256 | 35634373 |
| ENSE00001057190 | 35637158 | 35637352 |
| ENSE00002863255 | 35629036 | 35629281 |
| ENSE00003546939 | 35631140 | 35631224 |
| ENSE00003633828 | 35629520 | 35629673 |
| ENSE00003844581 | 35637442 | 35637685 |
Expression profiles
Bgee: expression breadth ubiquitous, 285 present calls, max score 95.23.
FANTOM5 (CAGE): breadth ubiquitous, TPM avg 53.8534 / max 400.3973, expressed in 1826 samples.
FANTOM5 promoters (4 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 175356 | 32.1480 | 1822 |
| 175357 | 19.7251 | 1815 |
| 175358 | 1.1424 | 596 |
| 175355 | 0.8380 | 573 |
Top tissues by expression
301 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| mucosa of transverse colon | UBERON:0004991 | 95.23 | gold quality |
| lower esophagus muscularis layer | UBERON:0035833 | 95.16 | gold quality |
| lower esophagus | UBERON:0013473 | 95.15 | gold quality |
| popliteal artery | UBERON:0002250 | 95.01 | gold quality |
| tibial artery | UBERON:0007610 | 95.00 | gold quality |
| esophagogastric junction muscularis propria | UBERON:0035841 | 94.94 | gold quality |
| aorta | UBERON:0000947 | 94.81 | gold quality |
| skin of leg | UBERON:0001511 | 94.80 | gold quality |
| left uterine tube | UBERON:0001303 | 94.77 | gold quality |
| thoracic aorta | UBERON:0001515 | 94.67 | gold quality |
| ascending aorta | UBERON:0001496 | 94.65 | gold quality |
| apex of heart | UBERON:0002098 | 94.65 | gold quality |
| muscle layer of sigmoid colon | UBERON:0035805 | 94.64 | gold quality |
| ectocervix | UBERON:0012249 | 94.61 | gold quality |
| body of uterus | UBERON:0009853 | 94.54 | gold quality |
| left coronary artery | UBERON:0001626 | 94.46 | gold quality |
| right coronary artery | UBERON:0001625 | 94.37 | gold quality |
| endocervix | UBERON:0000458 | 94.35 | gold quality |
| descending thoracic aorta | UBERON:0002345 | 94.34 | gold quality |
| coronary artery | UBERON:0001621 | 94.27 | gold quality |
| right ovary | UBERON:0002118 | 94.24 | gold quality |
| C1 segment of cervical spinal cord | UBERON:0006469 | 94.12 | gold quality |
| peripheral nervous system | UBERON:0000010 | 94.11 | gold quality |
| nerve | UBERON:0001021 | 94.11 | gold quality |
| tibial nerve | UBERON:0001323 | 94.11 | gold quality |
| skin of abdomen | UBERON:0001416 | 94.08 | gold quality |
| hindlimb stylopod muscle | UBERON:0004252 | 94.08 | gold quality |
| mucosa of stomach | UBERON:0001199 | 94.05 | gold quality |
| granulocyte | CL:0000094 | 94.01 | gold quality |
| gastrocnemius | UBERON:0001388 | 94.00 | gold quality |
Single-cell (SCXA)
Detected in 1 experiment(s), a significant marker in 1.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-ANND-3 | no | 0.00 |
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
9 targeting RBM42, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-5093 | 99.67 | 69.26 | 2291 |
| HSA-MIR-510-3P | 99.54 | 70.06 | 2965 |
| HSA-MIR-6722-3P | 99.45 | 67.62 | 1919 |
| HSA-MIR-1909-3P | 99.03 | 66.56 | 1662 |
| HSA-MIR-4738-3P | 98.98 | 67.98 | 1846 |
| HSA-MIR-29B-1-5P | 98.86 | 68.35 | 1364 |
| HSA-MIR-4260 | 98.78 | 65.37 | 848 |
| HSA-MIR-582-3P | 96.69 | 67.38 | 1019 |
| HSA-MIR-6090 | 91.01 | 62.65 | 222 |
Functional genomics
DepMap (CRISPR cell-line fitness): dependent in 73.8% of screened cell lines.
Literature-anchored findings (GeneRIF, showing 2)
- hnRNP K and RBM42 have a role in the maintenance of cellular ATP level in the stress conditions possibly through protecting their target mRNAs. (PMID:19170760)
- Biallelic variants in RBM42 cause a multisystem disorder with neurological, facial, cardiac, and musculoskeletal involvement. (PMID:37294900)
Cross-species orthologs
2 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| mus_musculus | Rbm42 | ENSMUSG00000036733 |
| rattus_norvegicus | Rbm42 | ENSRNOG00000024278 |
Protein
Protein identifiers
RNA-binding protein 42 — Q9BTD8 (reviewed: Q9BTD8)
Alternative names: RNA-binding motif protein 42
All UniProt accessions (5): Q9BTD8, K7EML2, K7EP90, K7EQ03, K7ER08
UniProt curated annotations — full annotation on UniProt →
Function. Binds (via the RRM domain) to the 3’-untranslated region (UTR) of CDKN1A mRNA.
Subunit / interactions. Interacts with HNRNPK.
Subcellular location. Nucleus. Cytoplasm.
Similarity. Belongs to the RRM RBM42 family.
Isoforms (4)
| UniProt ID | Names | Canonical? |
|---|---|---|
| Q9BTD8-1 | 1 | yes |
| Q9BTD8-2 | 2, RBM42a | |
| Q9BTD8-3 | 3 | |
| Q9BTD8-4 | 4, RBM42b |
RefSeq proteins (2): NP_001306042, NP_077297* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR000504 | RRM_dom | Domain |
| IPR012677 | Nucleotide-bd_a/b_plait_sf | Homologous_superfamily |
| IPR034215 | RBM42_RRM | Domain |
| IPR035979 | RBD_domain_sf | Homologous_superfamily |
| IPR050825 | RBM42_RBP45_47-like | Family |
Pfam: PF00076
UniProt features (28 total): modified residue 6, strand 6, splice variant 3, helix 3, region of interest 3, turn 2, compositionally biased region 2, initiator methionine 1, chain 1, domain 1
Structure
Experimental structures (PDB)
10 structures.
| PDB | Method | Resolution (Å) |
|---|---|---|
| 6QW6 | ELECTRON MICROSCOPY | 2.92 |
| 8H6E | ELECTRON MICROSCOPY | 3.2 |
| 8H6J | ELECTRON MICROSCOPY | 3.25 |
| 6QX9 | ELECTRON MICROSCOPY | 3.28 |
| 8QP8 | ELECTRON MICROSCOPY | 3.5 |
| 8QP9 | ELECTRON MICROSCOPY | 4.1 |
| 8QPK | ELECTRON MICROSCOPY | 4.2 |
| 8R0A | ELECTRON MICROSCOPY | 5.8 |
| 8R08 | ELECTRON MICROSCOPY | 6.1 |
| 8QXD | ELECTRON MICROSCOPY | 9.6 |
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q9BTD8-F1 | 63.47 | 0.18 |
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Post-translational modifications (6): 153, 158, 168, 181, 2, 135
Function
Pathways and Gene Ontology
Reactome pathways
1 pathways
| ID | Pathway |
|---|---|
| R-HSA-72163 | mRNA Splicing - Major Pathway |
MSigDB gene sets: 130 (showing top):
GOBP_NEGATIVE_REGULATION_OF_RNA_SPLICING, REACTOME_PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA, GOBP_PROTEIN_RNA_COMPLEX_ORGANIZATION, GOBP_RNA_SPLICING, MORF_PPP6C, REACTOME_MRNA_SPLICING, GOBP_REGULATION_OF_MRNA_SPLICING_VIA_SPLICEOSOME, SCHLOSSER_SERUM_RESPONSE_AUGMENTED_BY_MYC, MODULE_95, GOBP_RIBONUCLEOPROTEIN_COMPLEX_BIOGENESIS, GOBP_SPLICEOSOMAL_SNRNP_ASSEMBLY, GOBP_REGULATION_OF_RNA_SPLICING, REACTOME_METABOLISM_OF_RNA, GOCC_PRECATALYTIC_SPLICEOSOME, GOCC_SPLICEOSOMAL_TRI_SNRNP_COMPLEX
GO Biological Process (2): mRNA splicing, via spliceosome (GO:0000398), negative regulation of mRNA splicing, via spliceosome (GO:0048025)
GO Molecular Function (4): RNA binding (GO:0003723), mRNA binding (GO:0003729), nucleic acid binding (GO:0003676), protein binding (GO:0005515)
GO Cellular Component (5): nucleus (GO:0005634), nucleoplasm (GO:0005654), spliceosomal complex (GO:0005681), cytoplasm (GO:0005737), U4/U6 x U5 tri-snRNP complex (GO:0046540)
Reactome top-level categories
Rollup of top-1 pathways:
| Category | Pathways |
|---|---|
| mRNA Splicing | 1 |
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| binding | 2 |
| cellular anatomical structure | 2 |
| RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 1 |
| mRNA processing | 1 |
| mRNA splicing, via spliceosome | 1 |
| negative regulation of RNA splicing | 1 |
| regulation of mRNA splicing, via spliceosome | 1 |
| negative regulation of mRNA processing | 1 |
| nucleic acid binding | 1 |
| RNA binding | 1 |
| intracellular membrane-bounded organelle | 1 |
| nuclear lumen | 1 |
| nuclear protein-containing complex | 1 |
| ribonucleoprotein complex | 1 |
| intracellular anatomical structure | 1 |
| U5 snRNP | 1 |
| U4/U6 snRNP | 1 |
| spliceosomal tri-snRNP complex | 1 |
Protein interactions and networks
STRING
1730 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| RBM42 | HNRNPK | P61978 | 930 |
| RBM42 | DTD2 | Q96FN9 | 530 |
| RBM42 | ZMAT2 | Q96NC0 | 523 |
| RBM42 | GRAMD1A | Q96CP6 | 516 |
| RBM42 | PUF60 | Q9UHX1 | 499 |
| RBM42 | PRPF38A | Q8NAV1 | 497 |
| RBM42 | SMU1 | Q2TAY7 | 489 |
| RBM42 | TMEM208 | Q9BTX3 | 488 |
| RBM42 | TMEM9 | Q9P0T7 | 475 |
| RBM42 | ERFL | A0A1W2PQ73 | 447 |
| RBM42 | CCDC59 | Q9P031 | 430 |
| RBM42 | PRPF31 | Q8WWY3 | 427 |
| RBM42 | CNOT4 | O95628 | 422 |
| RBM42 | USP10 | Q14694 | 421 |
| RBM42 | FAM76A | Q8TAV0 | 419 |
IntAct
101 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| SNRPE | GEMIN2 | psi-mi:“MI:0914”(association) | 0.770 |
| RBM42 | HNRNPK | psi-mi:“MI:0915”(physical association) | 0.750 |
| HNRNPK | RBM42 | psi-mi:“MI:0915”(physical association) | 0.750 |
| PRPF3 | PRPF4 | psi-mi:“MI:0914”(association) | 0.730 |
| SART1 | PRPF3 | psi-mi:“MI:0914”(association) | 0.720 |
| SNRPD2 | GEMIN2 | psi-mi:“MI:0914”(association) | 0.710 |
| RBM42 | PSMA3 | psi-mi:“MI:0915”(physical association) | 0.670 |
| PSMA3 | RBM42 | psi-mi:“MI:0915”(physical association) | 0.670 |
| LSM5 | LSM1 | psi-mi:“MI:0914”(association) | 0.640 |
| SNRPB | SART1 | psi-mi:“MI:0914”(association) | 0.640 |
| PRR20D | RBM42 | psi-mi:“MI:0915”(physical association) | 0.560 |
| RBPMS2 | RBM42 | psi-mi:“MI:0915”(physical association) | 0.560 |
| RBM42 | SNRPA | psi-mi:“MI:0915”(physical association) | 0.550 |
| SNRPE | SNRPGP15 | psi-mi:“MI:0914”(association) | 0.530 |
| RPS2 | MPHOSPH10 | psi-mi:“MI:0914”(association) | 0.530 |
| KRR1 | MPHOSPH10 | psi-mi:“MI:0914”(association) | 0.530 |
| SNRPE | PRMT5 | psi-mi:“MI:0914”(association) | 0.530 |
| MAGEB2 | GTPBP10 | psi-mi:“MI:0914”(association) | 0.530 |
| RPS3 | ZNF316 | psi-mi:“MI:0914”(association) | 0.530 |
| CPSF6 | DDX39A | psi-mi:“MI:0914”(association) | 0.480 |
| CENPL | RBM42 | psi-mi:“MI:0915”(physical association) | 0.400 |
| SLC35B3 | RBM42 | psi-mi:“MI:0915”(physical association) | 0.400 |
| RBM42 | sctL | psi-mi:“MI:0915”(physical association) | 0.370 |
| FHL3 | RBM42 | psi-mi:“MI:0915”(physical association) | 0.370 |
| RBM42 | PPIL1 | psi-mi:“MI:0915”(physical association) | 0.370 |
| RBM42 | RBM4 | psi-mi:“MI:0915”(physical association) | 0.370 |
| RBM42 | RBFOX2 | psi-mi:“MI:0915”(physical association) | 0.370 |
| ESR1 | ESYT2 | psi-mi:“MI:0914”(association) | 0.350 |
BioGRID (399): RBM42 (Two-hybrid), RBM42 (Affinity Capture-MS), RBM42 (Two-hybrid), RBM42 (Two-hybrid), RBM42 (Affinity Capture-MS), FAM103A1 (Co-fractionation), METAP1 (Co-fractionation), RBM42 (Co-fractionation), RBM42 (Co-fractionation), RBM42 (Reconstituted Complex), CAMK2G (Affinity Capture-MS), CAMK2B (Affinity Capture-MS), CAMK2D (Affinity Capture-MS), SNRNP27 (Affinity Capture-MS), RBM45 (Affinity Capture-MS)
ESM2 similar proteins: A1L020, A2VDB3, A7Z019, B7FAS0, O15047, P17678, P48634, Q01JD1, Q05A36, Q0CA78, Q0P5L0, Q1LY77, Q3TKT4, Q3UE17, Q3UH66, Q5F3P8, Q5JWF2, Q5PQQ7, Q5TM26, Q5U5Q3, Q61473, Q63803, Q66KL9, Q6AXT7, Q6DRG1, Q6MG48, Q6R0H7, Q7TSC1, Q7XT42, Q86XN8, Q8BQ89, Q8CFT2, Q8CGW4, Q8IVB5, Q8IVW6, Q8TDN4, Q91V81, Q9BQW3, Q9BTD8, Q9D1Z2
Diamond homologs: A0A0A0LLY1, A2A5N3, A2VDB3, A5A6M3, A6NDE4, A6NEQ0, D4AE41, F1QB54, F4I3B3, O60176, O64380, O75526, O93235, P0C7P1, P0C8Z4, P0CB38, P0CP46, P0CP47, P0DJD3, P0DJD4, P10979, P11940, P20965, P21187, P29341, P31483, P32588, P38159, P38760, P39684, P49310, P49311, P52912, P60824, P60825, P60826, P61286, P70318, P84586, Q00539
SIGNOR signaling
1 interactions.
| A | Effect | B | Mechanism |
|---|---|---|---|
| RBM42 | “form complex” | “U4/U6.U5 snRNP complex” | binding |
Enriched among interaction partners
Reactome pathways and GO biological processes over-represented among this gene’s 100 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.
Reactome pathways:
| Pathway | Partners | Fold | FDR |
|---|---|---|---|
| Metabolism of non-coding RNA | 5 | 43.5× | 3e-06 |
| SARS-CoV-2 modulates host translation machinery | 10 | 30.7× | 7e-11 |
| SARS-CoV-1 modulates host translation machinery | 6 | 25.4× | 3e-06 |
| Eukaryotic Translation Initiation | 5 | 21.1× | 6e-05 |
| Cap-dependent Translation Initiation | 5 | 21.1× | 6e-05 |
| Formation of the ternary complex, and subsequently, the 43S complex | 7 | 20.7× | 2e-06 |
| Nonsense-Mediated Decay (NMD) | 6 | 19.2× | 1e-05 |
| Eukaryotic Translation Elongation | 5 | 19.1× | 9e-05 |
GO biological processes:
| GO term | Partners | Fold | FDR |
|---|---|---|---|
| spliceosomal snRNP assembly | 7 | 43.7× | 4e-08 |
| RNA splicing, via transesterification reactions | 6 | 40.3× | 1e-06 |
| U2-type prespliceosome assembly | 5 | 33.6× | 3e-05 |
| mRNA splicing, via spliceosome | 20 | 19.7× | 7e-18 |
| negative regulation of translation | 7 | 14.8× | 4e-05 |
| RNA splicing | 15 | 14.2× | 4e-11 |
| RNA processing | 6 | 14.1× | 3e-04 |
| regulation of alternative mRNA splicing, via spliceosome | 5 | 13.1× | 2e-03 |
Disease & clinical
Clinical variants and AI predictions
ClinVar
57 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 49 |
| Likely benign | 0 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
1217 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 19:35629365:GAGA:G | donor_gain | 1.0000 |
| 19:35629386:G:GT | donor_gain | 1.0000 |
| 19:35629515:TCCA:T | acceptor_loss | 1.0000 |
| 19:35629516:CCA:C | acceptor_loss | 1.0000 |
| 19:35629517:CAG:C | acceptor_loss | 1.0000 |
| 19:35629670:GCAG:G | donor_gain | 1.0000 |
| 19:35629671:CAG:C | donor_loss | 1.0000 |
| 19:35629673:GG:G | donor_loss | 1.0000 |
| 19:35629674:GTA:G | donor_loss | 1.0000 |
| 19:35631136:ACAG:A | acceptor_loss | 1.0000 |
| 19:35631137:CA:C | acceptor_loss | 1.0000 |
| 19:35631138:A:AG | acceptor_gain | 1.0000 |
| 19:35631138:A:C | acceptor_loss | 1.0000 |
| 19:35631139:G:A | acceptor_loss | 1.0000 |
| 19:35631139:G:GG | acceptor_gain | 1.0000 |
| 19:35631225:G:GA | donor_loss | 1.0000 |
| 19:35631226:TAA:T | donor_loss | 1.0000 |
| 19:35631326:A:AG | acceptor_gain | 1.0000 |
| 19:35631327:A:G | acceptor_gain | 1.0000 |
| 19:35631327:ACAG:A | acceptor_loss | 1.0000 |
| 19:35631328:CAGTT:C | acceptor_loss | 1.0000 |
| 19:35631329:A:AG | acceptor_gain | 1.0000 |
| 19:35631329:AGTT:A | acceptor_gain | 1.0000 |
| 19:35631329:AGTTG:A | acceptor_gain | 1.0000 |
| 19:35631330:G:A | acceptor_loss | 1.0000 |
| 19:35631330:G:GA | acceptor_gain | 1.0000 |
| 19:35631330:GT:G | acceptor_gain | 1.0000 |
| 19:35631330:GTT:G | acceptor_gain | 1.0000 |
| 19:35631330:GTTG:G | acceptor_gain | 1.0000 |
| 19:35631330:GTTGG:G | acceptor_gain | 1.0000 |
AlphaMissense
3047 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 19:35629268:G:C | A39P | 1.000 |
| 19:35629651:T:A | I87N | 1.000 |
| 19:35634319:C:A | R361S | 1.000 |
| 19:35634319:C:G | R361G | 1.000 |
| 19:35634320:G:C | R361P | 1.000 |
| 19:35634326:C:A | A363E | 1.000 |
| 19:35634329:C:A | A364E | 1.000 |
| 19:35634340:T:A | W368R | 1.000 |
| 19:35634340:T:C | W368R | 1.000 |
| 19:35634341:G:C | W368S | 1.000 |
| 19:35634342:G:C | W368C | 1.000 |
| 19:35634342:G:T | W368C | 1.000 |
| 19:35634346:G:A | D370N | 1.000 |
| 19:35634346:G:C | D370H | 1.000 |
| 19:35634347:A:G | D370G | 1.000 |
| 19:35634347:A:T | D370V | 1.000 |
| 19:35634352:A:C | S372R | 1.000 |
| 19:35634354:C:A | S372R | 1.000 |
| 19:35634354:C:G | S372R | 1.000 |
| 19:35634356:T:C | L373P | 1.000 |
| 19:35634364:T:A | W376R | 1.000 |
| 19:35634364:T:C | W376R | 1.000 |
| 19:35634365:G:C | W376S | 1.000 |
| 19:35634365:G:T | W376L | 1.000 |
| 19:35634366:G:C | W376C | 1.000 |
| 19:35634366:G:T | W376C | 1.000 |
| 19:35637160:G:T | D380Y | 1.000 |
| 19:35637161:A:C | D380A | 1.000 |
| 19:35637161:A:G | D380G | 1.000 |
| 19:35637161:A:T | D380V | 1.000 |
dbSNP variants (sampled 300 via entrez): RS1000042781 (19:35627353 C>A), RS1000562503 (19:35627770 C>T), RS1000656024 (19:35632315 T>C), RS1001160935 (19:35628963 TC>T,TCC), RS1001166338 (19:35628754 G>T), RS1001548827 (19:35630639 G>A), RS1001714485 (19:35637826 C>T), RS1002061874 (19:35630957 C>T), RS1002714289 (19:35635908 A>G), RS1002819234 (19:35637598 T>C), RS1002954134 (19:35629194 G>C), RS1003158431 (19:35631741 T>C), RS1003552434 (19:35627894 C>G), RS1003617760 (19:35628642 G>A), RS1003911480 (19:35633039 C>T)
Disease associations
OMIM: gene MIM:613232 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
0 associations (top):
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
32 total (human), top 30 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| sodium arsenite | increases expression | 2 |
| Lead | decreases expression | 2 |
| aristolochic acid I | increases expression | 1 |
| ginger extract | affects expression, increases abundance, affects cotreatment | 1 |
| triphenyl phosphate | affects expression | 1 |
| alpha-pinene | affects cotreatment, increases oxidation, increases abundance | 1 |
| bisphenol A | affects cotreatment, affects expression, increases abundance | 1 |
| beta-lapachone | increases expression | 1 |
| methacrylaldehyde | affects cotreatment, increases oxidation, increases abundance | 1 |
| 2,3,5-(triglutathion-S-yl)hydroquinone | increases ADP-ribosylation | 1 |
| ICG 001 | decreases expression | 1 |
| abrine | decreases expression, increases expression | 1 |
| 3-(2-hydroxy-4-(2-methylnonan-2-yl)phenyl)cyclohexan-1-ol | decreases expression | 1 |
| 4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid | decreases expression | 1 |
| Acrolein | increases abundance, affects cotreatment, increases oxidation | 1 |
| Air Pollutants | affects cotreatment, increases abundance, increases oxidation | 1 |
| Arsenic | affects methylation | 1 |
| Hydrogen Peroxide | affects expression | 1 |
| Ivermectin | decreases expression | 1 |
| Oils, Volatile | increases abundance, affects cotreatment, affects expression | 1 |
| Ozone | affects cotreatment, increases oxidation, increases abundance | 1 |
| Ribonucleotides | affects binding | 1 |
| Selenium | increases expression | 1 |
| Smoke | decreases expression | 1 |
| Thiram | increases expression | 1 |
| Valproic Acid | increases methylation | 1 |
| Vitamin E | increases expression | 1 |
| 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | decreases expression | 1 |
| Antirheumatic Agents | increases expression | 1 |
| Cadmium Chloride | increases expression | 1 |
Cellosaurus cell lines
1 cell lines: 1 transformed cell line
First 10 cell lines (id-ordered, not curated):
| Cellosaurus | Name | Category | Sex |
|---|---|---|---|
| CVCL_B3FU | Abcam HEK293T RBM42 KO | Transformed cell line | Female |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.